126 related articles for article (PubMed ID: 17365284)
1. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan.
Föger F; Kafedjiiski K; Hoyer H; Loretz B; Bernkop-Schnürch A
J Drug Target; 2007 Feb; 15(2):132-9. PubMed ID: 17365284
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan.
Föger F; Schmitz T; Bernkop-Schnürch A
Biomaterials; 2006 Aug; 27(23):4250-5. PubMed ID: 16618504
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein.
Föger F; Hoyer H; Kafedjiiski K; Thaurer M; Bernkop-Schnürch A
Biomaterials; 2006 Dec; 27(34):5855-60. PubMed ID: 16919723
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
6. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir.
Palmberger TF; Hombach J; Bernkop-Schnürch A
Int J Pharm; 2008 Feb; 348(1-2):54-60. PubMed ID: 17716840
[TBL] [Abstract][Full Text] [Related]
7. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine.
Werle M; Hoffer M
J Control Release; 2006 Mar; 111(1-2):41-6. PubMed ID: 16377016
[TBL] [Abstract][Full Text] [Related]
8. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
9. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
10. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
Su Y; Zhang X; Sinko PJ
Mol Pharm; 2004 Jan; 1(1):49-56. PubMed ID: 15832500
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
13. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK
Int J Pharm; 2008 Oct; 362(1-2):44-51. PubMed ID: 18620036
[TBL] [Abstract][Full Text] [Related]
14. Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system.
Hombach J; Hoyer H; Bernkop-Schnürch A
Eur J Pharm Sci; 2008 Jan; 33(1):1-8. PubMed ID: 17980561
[TBL] [Abstract][Full Text] [Related]
15. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
16. Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide.
Iqbal J; Shahnaz G; Perera G; Hintzen F; Sarti F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2012 Jan; 80(1):95-102. PubMed ID: 21964316
[TBL] [Abstract][Full Text] [Related]
17. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.
Luo S; Wang Z; Patel M; Khurana V; Zhu X; Pal D; Mitra AK
Int J Pharm; 2011 Jul; 414(1-2):77-85. PubMed ID: 21571053
[TBL] [Abstract][Full Text] [Related]
18. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
Berginc K; Trontelj J; Kristl A
Drug Metab Pharmacokinet; 2010; 25(3):307-13. PubMed ID: 20610890
[TBL] [Abstract][Full Text] [Related]
19. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
20. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
